(Z)-N-(4-fluorophenyl)-2-methoxy-3-(4-methoxyphenyl)acrylamide | 1357448-01-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (Z)-N-(4-fluorophenyl)-2-methoxy-3-(4-methoxyphenyl)acrylamide
• 英文别名: (Z)-N-(4-fluorophenyl)-2-methoxy-3-(4-methoxyphenyl)prop-2-enamide
• CAS: 1357448-01-1
• 化学式: C₁₇H₁₆FNO₃
• 分子量: 301.317
• InChiKey: PNYMAXGGFJUOBN-WJDWOHSUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(4-methoxyphenyl)-2-oxopropionic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 4.5h， 生成 (Z)-N-(4-fluorophenyl)-2-methoxy-3-(4-methoxyphenyl)acrylamide
  参考文献：
  名称：

  Synthesis of novel cinnamanilides as potential immunosuppressive agents

  摘要：

  A series of new cinnamanilides (6-40) were synthesized and their immunosuppressive activity and cytotoxicity were evaluated. Most of the cinnamanilides showed good immunosuppressive activity. Among the synthesized compounds, (Z)-N-(4-bromophenyl)-2-methoxy-3-(4-methoxyphenyl)acrylamide (37) and (Z)-2-methoxy-3-(4-methoxyphenyl)-N-p-tolylacrylamide (38) exhibited potent immunosuppressive activity (IC50 = 1.77 +/- 0.33 and 0.94 +/- 0.13 mu M) without significant cytotoxicity. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.10.027

文献信息

• Synthesis of novel cinnamanilides as potential immunosuppressive agents
  作者：Lei Shi、Lu Wang、Zhi Wang、Hai-Liang Zhu、Qiao Song

  DOI：10.1016/j.ejmech.2011.10.027

  日期：2012.1

  A series of new cinnamanilides (6-40) were synthesized and their immunosuppressive activity and cytotoxicity were evaluated. Most of the cinnamanilides showed good immunosuppressive activity. Among the synthesized compounds, (Z)-N-(4-bromophenyl)-2-methoxy-3-(4-methoxyphenyl)acrylamide (37) and (Z)-2-methoxy-3-(4-methoxyphenyl)-N-p-tolylacrylamide (38) exhibited potent immunosuppressive activity (IC50 = 1.77 +/- 0.33 and 0.94 +/- 0.13 mu M) without significant cytotoxicity. (C) 2011 Elsevier Masson SAS. All rights reserved.